Small Business Innovation Research · Small Business Technology Transfer
Kuria Therapeutics, Inc: SBIR & STTR awards
1 awards worth $399.9K to 1 companies since 2025 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
Kuria Therapeutics, Inc's federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 1 | 0 | $399.9K |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| IND-enabling studies of KTX-1161, a novel NRF2 activator for corneal endothelial disease · topic NEI | Kuria Therapeutics, Inc · Arkansas | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $399.9K | 2025-09-30 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.